World's first weight loss pill is made in the Triangle
Add Axios as your preferred source to
see more of our stories on Google.
Illustration: Annelise Capossela/Axios
North Carolina has quickly become a leading hub for the manufacturing of GLP-1 weight loss drugs, including the new Wegovy pill that's now on the market.
Why it matters: Having a pill form as opposed to a weekly shot is a big deal, largely because pills are cheaper to make than the widely popular injectables, NPR recently reported.
The big picture: One in eight U.S. adults take GLP-1 medications, around 32 million people, a recent KFF poll found.
- The transformation of GLP-1 drugs from niche to mainstream has been one of the most dramatic developments in health care this decade.
Yes, but: About 55% struggle to pay for them — with or without insurance — the poll also found.
How it works: The Wegovy pill is taken daily to both lose weight and address obesity's health complications, including cardiovascular disease.
- Like the injectables that came before it, the active ingredient is semaglutide, which emerged last decade as a diabetes treatment that also helped patients lose weight.
Zoom in: It's made "end to end" in the Triangle, a Novo Nordisk spokesperson told Axios, adding that more than 2,000 of the company's 10,000 U.S.-based employees work in North Carolina.
- Since the mid-1990s, the Danish pharmaceutical company says its invested $10 billion in manufacturing in the Triangle.
- Novo Nordisk has three sites in Clayton and one in Durham.
Flashback: Laura Rowley, vice president of life science economic development for the N.C. Biotechnology Center, said that while weight loss drugs continue to make headlines, North Carolina has been seeding investments for years.
- "So while it's news today in 2026, [Novo Nordisk] began building out the site, building out the workforce, over six years ago," Rowley told Axios.
State of play: A months-long shortage for GLP-1s ended around a year ago, and Novo Nordisk says its confident the company can meet demand for the pill version, which is currently approved only in the U.S., although it declined to share specifics on production or distribution.
- "It's early days, but what's clear is people have been waiting for" the medicine, and "there's only one," the spokesperson said.
Zoom out: Novo Nordisk is not the sole weight-loss drug manufacturer in the state. Its rival in the space, Eli Lilly, the maker of Zepbound and Mounjaro, has followed in its steps.
- Since 2020, Eli Lilly has expanded its presence in Research Triangle Park and in Concord, just north of Charlotte, and has taken market share from Novo Nordisk. Last year, Novo Nordisk laid off employees in the U.S. as a result.
Context: North Carolina invests heavily in workforce development to attract expansions in biomanufacturing. In return, companies like Novo Nordisk have invested back into the region.
- In September, Durham Technical Community College broke ground on a new biotechnology training center, funded in part through a $6 million gift from Novo Nordisk. It was the largest corporation donation in Durham Tech's history.
- "One of the reasons why manufacturing has been such an exciting area and has been so broadly embraced in so many communities in North Carolina is that there are a range of jobs," Rowley said. "It's not just for Ph.D.-level scientists, but actually, moreover, for folks that may have just a certificate beyond their high school education."
By the numbers: The Wegovy clinical trials found that most weight was shed after working up to a 25 mg daily dosage. That dosage would cost around $299 a month.
- A monthly supply of the shots varies by brand, but most are listed closer to $1,000.
What's next: Eli Lilly will likely also have an oral weight-loss drug on the market. The company filed for FDA approval in December, and the agency is expected to expedite the review.